Peptidomimetic inhibitors, macrocyclic

The same approach was recently used for the synthesis of a cyclopeptoid as potential inhibitor of the Tat/TAR complex of the HfV-1 virus (Scheme 24) [94, 95]. Two Ugi reactions were used to prepare fragment b that was coupled to fragment a to afford linear precursor c. The macrocyclic peptidomimetic d was obtained after cyclization employing Ugi reaction of amino acid c with paraformaldehyde and t-butyl isocyanide. 

Previous reviews on peptidomimetics have addressed pseudopeptides (11), macrocyclic mimetics (13), natural product mimetics (14), cyclic protease inhibitors (15), mimetics for receptor ligands (16-22), and earlier general overviews (23-29). This review will focus on the design process itself. Novel peptidomimetics in which the structural relationship between parent peptide and the peptidomimetic has been established by biophysical methods are used to clarify the principles. Successful approaches are highlighted to illustrate how these concepts are currently used. 

Many protease/peptidase inhibitor peptidomimetics include a-ketoamide moieties as key bioactive functionalities and the Passerini reaction provides a facile entry for their preparation through the oxidation of a-hydroxy amides. Researchers at Schering-Plough have utilized this strategy to synthesize a variety of a macrocyclic a-ketoamides towards the development of Hepatitis C virus (HCV) NS3 protease inhibitors. Aldehyde 56 was treated with allylisocyanide and acetic acid to give a-acyloxyamide... 

Evans has also developed an intramolecular version of the Cu(II)-assisted boronic acid O-arylation reaction and has applied it to the synthesis of macrocyclic biphenyl ether hydroxamic acid inhibitors of collagenase 1 and gelatinases A and B [65]. The reaction proceeds under sufficiently mild conditions to accommodate chemical functionalities commonly used in peptidomimetics synthesis (Scheme 3.44). 

---